Welcome to our dedicated page for Aditxt news (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt stock.
Aditxt Inc (ADTX) is a pioneering biotechnology company developing innovative solutions to reprogram immune responses, with applications in organ transplantation and autoimmune disorders. This dedicated news hub provides investors and researchers with timely updates on clinical advancements, regulatory milestones, and strategic partnerships.
Access authoritative reporting on ADTX's flagship programs including Adimune for transplant tolerance and AditxtScore diagnostic platforms. Track developments in Apoptotic DNA Immunotherapy (ADi) and other novel approaches to immune modulation. The curated news feed covers earnings reports, research collaborations, and product pipeline updates while adhering to financial disclosure standards.
Bookmark this page for consolidated access to press releases, clinical trial data disclosures, and expert analyses of ADTX's position in the competitive immunotherapy landscape. Stay informed about technological breakthroughs through verified updates from primary sources.
Aditxt, Inc. (NASDAQ: ADTX) provides updates on its innovation programs and M&A strategies. Its subsidiary, Pearsanta, was designated as the backup bidder for the assets of Lucira Health Inc., which include FDA-approved COVID-19 and flu tests. Aditxt raised concerns during the auction about the asset sale's fairness. Additionally, Aditxt formed Adivir, Inc. to target the antiviral market, with ongoing discussions to acquire assets from Cellvera. Meanwhile, Adimune is progressing with human clinical trials in Germany, focusing on psoriasis, and aims to add trials in the U.S. by Q4 2023. The company reported having approximately $2.8 million in cash as of December 31, 2022, highlighting potential financing challenges ahead.
Aditxt (NASDAQ: ADTX) has appointed Maureen Connolly as its Chief Content and Engagement Officer. Connolly brings over 25 years of experience in health and technology, previously serving as Editor in Chief at Everyday Health. Her role will focus on enhancing stakeholder engagement and communication strategies. Amro Albanna, the CEO, emphasized her fit for the role, expecting her to drive the company’s mission. Aditxt is known for its advancements in immune system technologies, offering personalized immune profiles and developing preclinical modulating technologies aimed at addressing autoimmune diseases and organ transplant rejections.
Aditxt, Inc. (NASDAQ: ADTX) has partnered with Riverside Management Group to enhance the growth and revenue strategies for its subsidiary, Pearsanta, Inc.. This collaboration aims to identify strategic M&A opportunities to scale AditxtScore™, a platform that profiles the immune system. The Company recognizes Pearsanta's potential in precision medicine and plans to improve operational efficiency through automation. Aditxt's initiatives position it for significant financial milestones in 2023, with a strong focus on the healthcare sector.
Aditxt, Inc. (NASDAQ: ADTX) announced the formation of a new wholly-owned subsidiary, Pearsanta, Inc., to enhance growth in their AditxtScore™ program. Headed by Anthony Voorhies, who has over 20 years of experience in clinical diagnostics, Pearsanta aims to accelerate revenue through strategic transactions and expanded product offerings. AditxtScore™ provides personalized immune profiles, critical for precision medicine. The subsidiary will operate from AditxtScore’s existing facilities in Richmond, highlighting the company's commitment to innovation and business expansion.
Aditxt, Inc. (NASDAQ: ADTX) has established a new subsidiary, Adimune, Inc., to advance its immunotherapeutic candidate, ADI™-100. A Clinical Trial Application (CTA) for human studies in psoriasis will be submitted, with trials expected to initiate in H2 2023. Dr. Joachim-Friedrich Kapp, an industry veteran, will lead Adimune as CEO. The company has reported positive toxicology results for ADI™-100, which aims to restore immune tolerance. This move aligns with Aditxt's strategy to commercialize innovative technologies and represents a significant milestone in their development pipeline.
Aditxt, Inc. (NASDAQ: ADTX) announced the commencement of GMP manufacturing for its drug candidate ADI™-100 under the Adimune™ program, aiming to start first-in-human trials in the second half of 2023, pending regulatory approvals. Targeting autoimmune diseases, it will initially focus on psoriasis. Previous toxicology studies confirm ADI™-100's safety. The global psoriasis treatment market is projected to grow from $26.37 billion in 2022 to $47.24 billion by 2029, reflecting a strong potential for Adimune’s innovative approach that restores immune tolerance rather than suppressing it.
Aditxt, Inc. (NASDAQ: ADTX) announced the publication of a mathematical model for predicting the durability and decay rate of neutralizing antibodies (NAb) to SARS-CoV-2 in the Journal of Theoretical Biology. Developed with Dr. Lisette de Pillis, the model aims to evaluate immune responses to COVID-19 vaccination. It provides insights that could help tailor immunization protocols and aid in vaccine development. Potential applications include identifying vulnerable populations, accelerating clinical trials, and optimizing booster timing.
Aditxt, Inc. (NASDAQ: ADTX) has been featured by FedEx in a video presentation highlighting its AditxtScore™ technology, which helps monitor immune responses to COVID-19. The company collaborates with FedEx to ensure timely delivery of blood samples critical for processing and generating personalized immune profiles using proprietary technologies. Aditxt aims to enhance understanding of immune status, assisting healthcare professionals in making informed vaccination decisions.
Aditxt, Inc. (NASDAQ: ADTX) has confirmed compliance with Nasdaq's minimum bid price and stockholders' equity requirements. This compliance follows a recent reverse stock split and a successful $20 million public offering. CEO Amro Albanna highlighted that these steps are crucial for the company's ongoing programs, which include AditxtScore™, Adimune™, and Adivir™, aimed at monitoring and modulating the immune system. Aditxt continues to develop technologies to personalize immune profiles and address organ rejection, autoimmune diseases, and allergies.
Aditxt, Inc. (Nasdaq: ADTX) has completed a reverse stock split and closed a $20 million public offering, crucial for advancing its key programs: AditxtScore™, Adimune™, and Adivir™. The reverse split positions the company for compliance with Nasdaq requirements, with 3,708,647 shares outstanding. AditxtScore™ is seeing revenue growth, while Adimune™ is preparing for clinical trials and Adivir™ holds potential revenue from a partnership with Cellvera. This development could lead to improved financial health and product advancement in immune system technologies in 2023.
FAQ
What is the current stock price of Aditxt (ADTX)?
What is the market cap of Aditxt (ADTX)?
